Fleisch, H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient. Parthenon Publishing: London 1995.
Russell, R.G.G., Fleisch, H. Inorganic pyrophosphate and pyrophosphatases in calcification and calcium homeostasis. Clin Orthop 1970, 69: 101-7.
Fleisch, H. Diphosphonates: History and mechanisms of action. Metab Bone Dis Relat Res 1981, 3: 279-88.
Treschel, U., Stutrer, A., Fleisch, H. Hypercalcaemia induced with a retinoid in thyroparathyroidectomized rats. New model to study bone resorption in vivo. J Clin Invest 1986, 80: 1979-86.
Fleisch, H. Experimental basis for the use of bisphosphonates in Paget$s disease of bone. Clin Orthop Relat Res 1987, 217: 72-8.
Reginster, J.Y. (Ed.). Ostéoporose Postménopausique. Traitement Prophylactique. Masson: Paris 1993.
Riggs, B.L., Melton, L.J. Involution osteoporosis. Am J Med 1986, 314: 1676-1684.
Reginster, J.Y.L. Les bisphosphonates constituent-ils un réel progrès thérapeutique dans l'ostéoporose? Méd Hyg 1996, 54: 1497-501.
Plosker, G.L., Goa, K.L. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994, 47: 945-82.
Chesnut, C.H. Synthetic calcitonin, diphosphonates and anabolic steroids in the treatment of postmenopausal osteoporosis. In: Osteoporosis 1984. Christiansen, C., Arnaud, C.D., Nordin B.E.C. et al. (Eds.). Osteopress: Copenhagen 1984, 594-655.
Giannini, S., D'Angelo, A., Malvasi, L. et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 1993, 14: 137-41.
Filipponi, P., Pedetti, M., Fedell, L. et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995, 10: 697-703.
Filipponi, P., Cristallini, S., Rizzello, E. et al. Cyclical intravenous clodronate in postmenopausal osteoporosis: Results of a long-term clinical trial. Bone 1996, 18(2): 179-84.
Filipponi, P., Cristallini, S., Rizzello, E., Policani, G., Gregorio, F., Boldrini, S. 6-Year cyclical intravenous clodronate in postmenopausal osteoporosis: Effect on bone mass and vertebral fractures. Osteoporos Int 1996, 6(Suppl. 1): 260.
Storm, T., Thamsborg, G., Steinich, T., Genant, H.K., Sorense, O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl J Med 1990, 322: 1265-71.
Watts, N.B., Harris, S.T., Genant, H.K. et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New Engl J Med 1990, 323: 73-9.
Pacifici, R., MacMurtry, C., Vered, I., Rupich, R., Avioli, L.V. Coherence therapy does not prevent axial bone loss in osteoporotic women: A preliminary comparative study. J Clin Endocrinol Metab 1988, 66: 747-53.
Smith, M.L., Fogelman, I., Hart, D.M., Scott, E., Bevan, I., Leggate, I. Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int 1989, 44: 74-9.
Harris, S.T., Watts, N.B., Jackson, R.D. et al. Four-year trial of intermittent cyclical etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 1993, 95: 557-67.
Axelrod, D.W., Teitelbaum, S.L. Results of long-term cyclical etidronate therapy: Bone histomorphometry and clinical correlates. J Bone Miner Res 1994, 9(Suppl. 1): 136.
Thomas, T., Lafage, M.H., Alexandre, C. Atypical osteomalacia after 2 years etidronate intermittent cyclic administration in osteoporosis. J Rheum 1995, 22: 11.
Storm, T., Thamsborg, G., Kollerup, G., Sorensen, H.A. Five years of intermittent cyclical etidronate therapy increases bone mass and reduces vertebral fracture rates in postmenopausal osteoporosis. Bone Miner 1992, 17(Suppl. 1):24.
Jackson, R.D., Harris, S.T., Genant, H.K. et al. Cyclical etidronate treatment of postmenopausal osteoporosis: 4-year experience. Bone Miner 1992, 17(Suppl. 1): 154.
Miller, P., Huffer, W., Mac Intyre, D. et al. Bone histomorphometry after long-term treatment with cyclical phosphorus and etidronate. Bone Miner 1992, 17(Suppl. 1): 23.
Storm, T., Sorensen, H.A., Thamsborg, G. et al. Bone histomorphometric changes after up to seven years of cyclical etidronate treatment. J Bone Miner Res 1996, 11(Suppl. 1): 151.
Toolan, B.C., Shea, M., Myers, E.R. et al. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanisms in rats. J Bone Miner Res 1992, 7: 1399-406.
Balena, R., Toolan, B.C., Shea, M. et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993, 92: 2577-86.
Hosking, D.J., McClung, M.R., Ravn, P. et al. Alendronate in the prevention of osteoporosis: EPIC study two-year results. J Bone Miner Res 1996, 11(Suppl. 1): 133.
Chesnut, C.H., Mc Clung, M.R., Ensrud, K.E. et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995, 99: 144-52.
Devogelaer, J.P., Broll, H., Correa-Rotter, R. et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996, 18: 141-50.
Liberman, U., Weiss, S.R., Broll, J. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl J Med 1995, 333: 1437-43.
Black, D.M., Cummings, S.R., Karpf, D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348: 1535-41.
De Groen P.C., Lubbe D.F., Hirsch L.J. et al. Esophagitis associated with the use of alendronate. New Engl J Med 1996, 335: 1016-21.
Maconi, G., Porro, G.B. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995, 90: 1889-90.
Valkema, R., Vismans, F.J.E., Papapoulos, S.E., Pauwels, K.J., Bijvoet, O.L.M. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989, 5: 183-92.
Reid, I.R., Wattie, D.J., Evans, M.C., Gamble, G.D., Stapleton, J.P., Cornish, J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994, 79: 1595-9.
Lufkin, E.G., Argueta, R., Whitaker, M.D. et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994, 4: 320-2.
Devogelaer, J.P., Esselinckx, W., Nagant De Deuxchaisnes, C.A. A randomized, controlled trial of APD (disodium pamidronate) given intravenously with and without sodium fluoride in involutional osteoporosis. J Bone Miner Res 1992, 5(Suppl. 2): 252.
Muhlbauer, R.C., Bauss, F., Schenk, R. et al. Ibandronate, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991, 6: 1003-11.
Schurch, M.A., Rizzoli, R., Slosman, D., Bonjour, J.-P. Protein supplements increase serum IGF-1 and prevent proximal femur bone loss in elderly with a recent hip fracture. Osteoporos Int 1996, 6(Suppl. 1): 94.
Ravn, P., Clemmesen, B., Riis, J., Christiansen, C. The effect on bone mass and bone markers of different doses of ibandronate - A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study. Osteoporos Int 1996, 6(Suppl. 1): 301.
Tobias, J.H., Laversuch, C.V., Wilson, N., Robins, P. Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in postmenopausal women. Calcif Tissue Int 1996, 59: 407-9.
Wronski, T.J., Yen, C.F., Scott, K.S. Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res 1991, 6: 387-94.
Ettinger, B., Genant, H., Bekker, P., Shen, I., Axelrod, D. A pilot three-year study of risedronate in women with breast cancer and chemotherapy-induced menopause. J Bone Miner Res 1995, 10(Suppl. 1): 198.
Delmas, P.D., Hardouin, C., Confavreux, E., Hardy, P., Bremond, A. Intermittent risedronate prevents bone loss in women with artificial menopause induced by chemotherapy of breast cancer. J Bone Miner Res 1995, 10(Suppl. 1): 200.
Mortensen, L., Bekker, P., Ouweland, F.V.D. et al. Prevention of early postmenopausal bone loss by risedronate: A two-year study. J Bone Miner Res 1995, 10(Suppl. 1): 140.
Langdahl, B., Eriksen, E.F., Mortensen, L. Histomorphometry from a three-year risedronate bone loss prevention study. J Bone Miner Res 1995, 10(Suppl. 1): 199.
McClung, M., Bensen, W., Bolognese, M. et al. Risedronate treatment of postmenopausal women with low bone mass: Preliminary data. Osteoporos Int 1996, 6(Suppl. 1): 257.
Zegels, B., Balena, R., Eastell, R., Russell, R.G.G., Pack, S.E., Reginster, J.Y. Effect of risedronate on collagen cross links in postmenopausal osteoporosis. J Bone Miner Res 1995, 10(Suppl. 1): 455.
Taquet, A.N., Clemmensen, B., Zegels, B. et al. A three-year double-blind placebo controlled study of risedronate in postmenopausal osteoporosis. Osteoporos Int 1996, 6(Suppl. 1): 262.
Ammann, P., Rizzoli, R., Caverzasio, J., Shigematsu, T., Slosman, D., Bonjour, J.-P. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density. J Bone Miner Res 1993, 8: 1491-8.
Geusens, P., Nijs J., Van Der Perre, G. et al. Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys. J Bone Miner Res 1992, 7: 599-609.
Chastagnier, D., Barbier, A., de Vernejoul, M.C., Geusens, P., Lacheretz, F. Effects of two bisphosphonates (tiludronate and etidronate) on bone healing. J Bone Miner Res 1993, 8(Suppl. 1): 236.
Reginster, J.Y., Colson, F., Morlock, G., Combe, B., Ethgen, D., Geusens, P. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. Arthritis Rheum 1992, 35: 967-74.
Roux, C., Gennari, C., Farrerons, J. et al. Comparative, prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in Paget's disease of bone. Arthritis Rheum 1995, 38: 851-8.
Reginster, J.Y., Lecart, M.P., Deroisy, R. et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989, ii: 1469-71.
Roux, C., Deroisy, R., Basse-Cathalinat, B. et al. Prevention of early postmenopausal bone loss with oral tiludronate. Osteoporos Int 1996, 6(Suppl. 1): 249.
